H.C. Wainwright assumed coverage of InflaRx (IFRX) with a Buy rating and $6 price target The company has an approved asset whose entrance onto the market is a validation of the anti-C5a/C5aR strategy in inflammation, the analyst tells investors in a research note. The firm says InflaRx is “flying under the radar with investors.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IFRX: